FDA reviews Merck & Co’s Keytruda in new ‘tumour agnostic’ useMerck & Co’s Keytruda cancer immunotherapy could be set for another indication, which could open up for use Share XFDA reviews Merck & Co’s Keytruda in new ‘tumour agnostic’ usehttps://pharmaphorum.com/news/fda-reviews-merck-cos-keytruda-in-new-tumour-agnostic-use/
Cancer Research UK cuts research funding as COVID-19 hits incomeCancer Research UK has cut funding to its research activities, as the charity faces a cut to its Share XCancer Research UK cuts research funding as COVID-19 hits incomehttps://pharmaphorum.com/news/cancer-research-uk-cuts-funding-as-covid-19-hits-income/
Servier to acquire Danish cancer biotech SymphogenFrance’s Servier has signed a deal to buy the Danish biotech Symphogen, which specialises in antibody-based therapies for Share XServier to acquire Danish cancer biotech Symphogenhttps://pharmaphorum.com/news/servier-to-acquire-danish-biotech-symphogen/
AI and cancer care: 3 ways artificial intelligence may transform cancer outcomesArtificial intelligence (AI) and machine learning (ML) are transforming the way cancers are detected and staged, offering new Share XAI and cancer care: 3 ways artificial intelligence may transform cancer outcomeshttps://pharmaphorum.com/views-analysis-digital/ai-cancer-care-3-ways-artificial-intelligence-transform-cancer-outcomes/
BMS’ big merger bet is still on with latest CAR-T filingBristol-Myers Squibb and development partner bluebird bio have filed their multiple myeloma CAR-T with the FDA, the final Share XBMS’ big merger bet is still on with latest CAR-T filinghttps://pharmaphorum.com/news/bms-and-bluebird-file-multiple-myeloma-car-t/
Macrophage Pharma goes for gold with new funding roundRichard Staines spoke with Soren Bregenholt, the new CEO of Macrophage Pharma, about the company’s strategy encompassing both Share XMacrophage Pharma goes for gold with new funding roundhttps://pharmaphorum.com/r-d/views-analysis-r-d/macrophage-pharma-goes-for-gold-with-new-funding-round/
AZ’s immunotherapy combo fails in phase 3 lung cancer trialAstraZeneca’s Imfinzi plus standard chemo improves overall survival in untreated extensive-stage small cell lung cancer – but a Share XAZ’s immunotherapy combo fails in phase 3 lung cancer trialhttps://pharmaphorum.com/news/azs-immunotherapy-combo-fails-in-phase-3-lung-cancer-trial/
AZ’s cediranib falls short again in ovarian cancer combinationAstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it Share XAZ’s cediranib falls short again in ovarian cancer combinationhttps://pharmaphorum.com/news/azs-cediranib-falls-short-again-in-ovarian-cancer-combination/
Takeda’s Ninlaro falls short in first line multiple myelomaTakeda’s Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgene’s Revlimid Share XTakeda’s Ninlaro falls short in first line multiple myelomahttps://pharmaphorum.com/news/takedas-ninlaro-falls-short-in-first-line-multiple-myeloma/
